Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia.

por Barosi, G., Marchetti, M., Liberato, N. L.
Publicado 1998

P982: MYELOID-DERIVED SUPPRESSOR CELLS: CHARACTERIZATION IN PERIPHERAL BLOOD AND SPLEEN TISSUE OF PATIENTS WITH MYELOFIBROSIS

por Campanelli, R., Bonometti, A., Massa, M., Abbà, C., Villani, L., Carolei, A., Catarsi, P., Paulli, M., Barosi, G., Boveri, E., Rosti, V.
Publicado 2022

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

por Tefferi, A, Al-Ali, H K, Barosi, G, Devos, T, Gisslinger, H, Jiang, Q, Kiladjian, J-J, Mesa, R, Passamonti, F, Ribrag, V, Schiller, G, Vannucchi, A M, Zhou, D, Reiser, D, Zhong, J, Gale, R P
Publicado 2017

P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREAT...

por Gupta, V., Yacoub, A., Verstovsek, S., Mesa, R. A., Harrison, C. N., Barosi, G., Kiladjian, J.-J., Deeg, H. J., Fazal, S., Foltz, L., Mattison, R. J., Miller, C. B., Parameswaran, V., Hernandez, C., Zhang, J., Talpaz, M.
Publicado 2022

Erratum: A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

por Tefferi, A, Al-Ali, H K, Barosi, G, Devos, T, Gisslinger, H, Jiang, Q, Kiladjian, J-J, Mesa, R, Passamonti, F, McMullin, M F, Ribrag, V, Schiller, G, Vannucchi, A M, Zhou, D, Reiser, D, Zhong, J, Gale, R P
Publicado 2017

Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms

por Pietra, D, Rumi, E, Ferretti, V V, Buduo, C A Di, Milanesi, C, Cavalloni, C, Sant'Antonio, E, Abbonante, V, Moccia, F, Casetti, I C, Bellini, M, Renna, M C, Roncoroni, E, Fugazza, E, Astori, C, Boveri, E, Rosti, V, Barosi, G, Balduini, A, Cazzola, M
Publicado 2016